Suggestions
Jun Axup
COO at E11 Bio, a neuroscience Focused Research Organization
Jun Axup, PhD, is the Chief Operating Officer at E11 Bio, a non-profit focused research organization dedicated to advancing neuroscience and improving human health through innovative technologies. She has been in this role since March 2023, where she oversees daily operations and strategic direction for the organization.23
Background and Education
Dr. Axup holds a PhD in chemical biology from the Scripps Research Institute. Her doctoral research involved developing targeted immuno-oncology drugs using unnatural amino acids.34 Before joining E11 Bio, she served as the Chief Science Officer and Partner at IndieBio, a prominent life science accelerator, where she played a pivotal role in funding and advising over 170 biotech companies aimed at enhancing human and planetary health.12
Professional Experience
- E11 Bio (2023 - Present): As COO, she leads operational strategies to amplify the organization's impact in neuroscience.
- IndieBio (2016 - 2022): In her previous role, she was instrumental in scientific programming and investment decisions while fostering a community of entrepreneurs in the biotech sector.23
- Other Ventures: Dr. Axup has co-founded several companies, including MYi Diagnostics and Discovery, which focused on multiplex proteomics for precision medicine, and Biochemies, which created educational science toys.24
Interests
Beyond her professional endeavors, Jun Axup is passionate about brain longevity and engages in creative pursuits such as writing science-themed songs on the ukulele.3
Highlights
This Week in Neuro 🧠
AI-in-the-loop creates personalized deep brain electrical stimulation dosing for Parkinson's patients. https://lnkd.in/gE7AVjum
Spontaneous mitochondrial DNA gene transfer into nuclear DNA is found to be more common than previously thought, especially in certain brain regions and fibroblasts. These random insertions can be disruptive to normal function and are linked to shorter lifespan. https://lnkd.in/gwD-97JB
Alzheimer's disease decreases glucose metabolism in astrocytes. Inhibiting an overactive enzyme in this pathway rescues synaptic plasticity and memory function in mice. https://lnkd.in/gxDjhEcm
This Week in Neuro 🧠
A new ARPA-H program for brain stem cell replacement led by Jean Herbert asks: Can we 'Ship of Theseus' our way out of brain aging? https://lnkd.in/gyfC48iz
Dysfunction in the glymphatic system that drains waste from your brain can lead to neurodegeneration. A drug might restore this function. https://lnkd.in/gnZFZvtc
Lykos Therapeutics' MDMA-assisted therapy was rejected by the FDA, setting new guidelines and clinical expectations for the future of psychedelic medicine. https://lnkd.in/gaxEtSUU
